Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis' ra­dio­phar­ma drug wins ap­proval in tough-to-treat prostate can­cer pa­tients

One of the key ways in which No­var­tis CEO Vas Narasimhan hopes to stave off gener­ic com­pe­ti­tion took a gi­ant leap for­ward Wednes­day af­ter­noon.

The FDA ap­proved Lu-PS­MA-617, No­var­tis’ ra­di­oli­gand pro­gram ac­quired in the $2.1 bil­lion buy­out of En­do­cyte back in 2018, to treat PS­MA-pos­i­tive metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer. No­var­tis will brand the drug as Plu­vic­to, and a spokesper­son told End­points News that the drug’s whole­sale ac­qui­si­tion cost will be set at $42,500 per dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.